Navigation Links
Cantel Medical Board of Directors Authorizes Increase in Semiannual Dividend
Date:10/21/2010

LITTLE FALLS, N.J., Oct. 21 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) announced today that its Board of Directors approved an increase in its semiannual cash dividend to $0.06 per outstanding share of the Company's Common Stock. The dividend is payable on January 28, 2011 to shareholders of record at the close of business on January 14, 2011.

Charles M. Diker, Chairman of the Board, said, "We are pleased to announce the dividend increase, which will raise our annual dividend payment from $0.10 to $0.12 per share. The increase demonstrates Cantel's strong financial position and our confidence in Cantel's future performance."

Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.

For further information, visit the Cantel website at www.cantelmedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events
'/>"/>

SOURCE Cantel Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
2. Cantel Medical Corp. To Hold Conference Call To Discuss Fourth Quarter and Fiscal 2009 Results
3. Cantel Medicals Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza
4. Cantel Medical Named to the Forbes 2009 List of the 200 Best Small Companies in America
5. Cantel Medical Corp. to Present at the Sidoti Emerging Growth Research Institutional Investor Forum
6. Cantel Medical Authorizes Semiannual Dividend
7. Cantel Medical Corp. to Hold Conference Call to Discuss Results for its First Quarter Ended October 31, 2009
8. Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase
9. Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2010
10. Cantel Medical Reports 29% Increase in Net Income - EPS of $0.29 vs. $0.23 for Quarter Ended January 31, 2010
11. Cantel Medical Corp. to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014 /PRNewswire-iReach/ -- ... the basis of products, methods, applications, end users, ... highest growth in the microbial identification market. This ... consumable costs (per test) and the time required ... and continuous technological advancements. Furthermore, genotypic methods have ...
(Date:7/29/2014)... THOUSAND OAKS, Calif., July 29, 2014 Amgen ... for the second quarter of 2014. Key results include: ... million, with 8 percent product sales growth driven by ... (etanercept), Kyprolis ® (carfilzomib), Prolia ® (denosumab) ... grew 25 percent to $2.37, driven by higher revenues ...
(Date:7/29/2014)... LOUIS, July 29, 2014  Express Scripts Holding Company ... net income attributable to Express Scripts stockholders of $515.2 ... diluted share, as detailed in Table 4, was $1.23 ... are well positioned to serve our clients with scale, alignment ... to improve the health outcomes of our members," stated George ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
... but,Underscore Need for Improved Patient Communication, Lifestyle,Management ... Elevated,Blood Pressure, NEW YORK, May 19, 2007 ... Harris Interactive(R) for the Hypertension Education,Foundation (HEF) ... Inc. (ASH) Twenty-Second Annual Scientific Meeting,and Exposition ...
... SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medical,professionals ... problem of,hospital-acquired gram-negative pneumonia may have a ... candidate being,developed by Nektar Therapeutics (Nasdaq:NKTR)., Results ... the use of,NKTR-061 (Inhaled Amikacin) to treat ...
Cached Medicine Technology:Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 2Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 3Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 4Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 5Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 6Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
(Date:7/29/2014)... July 29, 2014 (HealthDay News) --,The time at which ... their chances for survival, new research suggests. Showing ... or during holidays is associated with a 13 percent ... hours, researchers report. Every year, more than 250,000 ... severe type of heart attack, which is caused by ...
(Date:7/29/2014)... 2014 (HealthDay News) -- Chlorine helps keep pool water ... to develop eye infections, doctors say. Pool ... as blurry vision, said Dr. Sampson Davis, an emergency ... Jersey. It,s important to understand why this happens, ... the outer film layer of the eye that helps ...
(Date:7/29/2014)... Las Vegas, Nevada (PRWEB) July 29, 2014 ... has reappointed Holland & Hart LLP ’s Connie ... Bar Foundation. She currently serves as President of the Foundation. ... from 2011-2012. , Akridge is a partner at Holland & ... variety of litigation and regulatory/administrative matters to insurance and healthcare ...
(Date:7/29/2014)... 2014 Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ... suffered serious liver injuries due to the acetaminophen ... a multidistrict litigation underway in U.S. District Court, ... According to an Order dated July 23rd, the ... bellwether case and discovery issues. Among other things, ...
(Date:7/29/2014)... Dennis Thompson HealthDay Reporter , ... diet and good sleep can protect the body against the ... at a cellular level, researchers report. A study involving ... to increased shortening of telomeres, the protective caps at the ... "We found that over a one-year period, the more stressors ...
Breaking Medicine News(10 mins):Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Protect Your Eyes When Hitting the Pool 2Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 3
... 25 The University of Texas ... add Elekta,s Leksell Gamma Knife (R) Perfexion(TM), ... to treat one or more lesions in the ... oncology department.(Photo: http://www.newscom.com/cgi-bin/prnh/20090225/CL74742 )"Leksell Gamma Knife ...
... CAMBRIDGE, Mass. and GAITHERSBURG, Md., Feb. 25 ... Inc., a systems biology company focused on ... better develop novel therapeutics, molecular diagnostics and ... signed a partnership agreement with Gene Logic, ...
... Feb. 25 Aton Pharma, Inc., a,diversified specialty ... marketing rights to the TIMOPTIC(R) product line from ... non-selective beta-adrenergic receptor,blocking agent indicated for the treatment ... or open-angle glaucoma. As many as 2.25,million Americans ...
... Head Company,s Network of International Subsidiaries and DistributorsWESTFORD, Mass., ... CYNO ), a leading developer and manufacturer of ... announced the appointment of William T. Kelley as Senior ... responsible for the company,s direct subsidiaries in four European ...
... also urges higher cigarette taxes, more oversight of advertising ... All tobacco products in the United States should be ... released Wednesday by a panel of 26 of the ... "Bold thinking is required to reverse the catastrophic projections ...
... Maine, Feb. 25 Millions of Americans live without ... services provided by non-profit dental clinics become increasingly important. ... of Maine Dental Health for AllTM program is helping ... with an estimated 134,000 additional patient visits since its ...
Cached Medicine News:Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 2Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 2Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 4Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 2Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 3Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 2Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 3Health News:Experts Call for FDA Regulation of Tobacco Products 2Health News:Tom's of Maine Dental Health for All(TM) Program Works With Customers and Retailers to Provide Access to Oral Health Care 2Health News:Tom's of Maine Dental Health for All(TM) Program Works With Customers and Retailers to Provide Access to Oral Health Care 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: